Frontpage (v0)
MultiPark
MultiPark (Multidisciplinary Parkinson and Alzheimer Research) is a strategic research area (SRA) supported by the Swedish Government. Through a comprehensive scientific programme we aim at unraveling basic disease mechanisms, improving diagnostics precision, and developing efficient methods of treatment and carefor people affected by neurodegenerative diseases. Building on a tradition of excellence in dopamine research at Lund University, the MultiPark programme was originally focused on Parkinson’s disease. Our network has gradually expanded to incorporate excellent research groups studying Alzheimer´s and Huntington´s disease, or neurodegeneration secondary to brain trauma and stroke.
Calendar
News
15 Apr 2025 | News
More opportunities to test for Alzheimer’s using new analytical method
A simpler method of analysing blood samples for Alzheimer’s disease has been tested in a large multicentre study, led by Lund University in Sweden.
“This is a major step in bringi...
14 Apr 2025 | News
A new reliable blood marker reveals the extent of Alzheimer’s pathology in the brain
Researchers at Lund University and Washington University have identified a blood marker that reflects the amount of Alzheimer’s pathology in the brain. This discovery may play a ke...
2 Apr 2025 | News
From molecule to patient – Six promising projects to advance Parkinson's research
What role does an inflammatory protein have in disease development? Which neuronal circuits cause different symptoms? How may diabetes affect Parkinson’s disease? Can motor signs b...
14 Mar 2025 | News
MultiPark grows – new research groups
This year, MultiPark has the pleasure of welcoming two new research groups. The Mackenzie Lab aims to decode the neurobiological underpinnings of emotion through experimental studi...
13 Feb 2025 | News
Cracking the Alzheimer’s Code: How Brain Trauma Triggers Disease
A study at Lund University reveals that traumatic brain injury alters the small vessels in the brain, resulting in an accumulation of amyloid beta — a hallmark of Alzheimer’s disea...
